National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

Rights & Permissions

topleft topright

Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report (2008)
Board on Global Health (BGH)

Citation Manager

. "Letter Report." Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. Washington, DC: The National Academies Press, 2008.

Please select a format:

BibTeX EndNote RefMan


Page
37
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report

TABLE 14 Incidence of Hospital Admission with Malaria Parasites from Randomization Up to 5 Months After the Last Dose of SP

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Overall

Placebo

Episodes

52

91

79

35

38

16

 

PYAR

310

1401

628

710

561

717

 

Incidence

0.17

0.06

0.13

0.05

0.07

0.02

 

IPTi with SP

Episodes

27

58

69

38

44

10

 

PYAR

309

1405

634

709

580

709

 

Incidence

0.09

0.04

0.11

0.05

0.08

0.01

 

Efficacy (95% CI)

49 (15, 70)

36 (10, 55)

15 (−21, 40)

−9 (−72, 31)

−12 (−75, 28)

37 (−43, 72)

21 (−2, 38)

p-value

0.009

0.011

0.37

0.73

0.61

0.27

0.066

NOTE: PYAR: Person-years at risk. The committee used Stata to calculate the overall efficacy and its 95 percent confidence limit.

SOURCE: Data from the Report of the Statistical Working Group (IPTi Consortium, 2007b).

TABLE 15 Incidence of All-Cause Hospital Admissions from Randomization Up to 5 Months After the Last Dose of SP

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Overall

Placebo

Episodes

172

445

359

94

NA

73

 

PYAR

303

1400

632

710

NA

714

 

Incidence

0.57

0.32

0.57

0.13

NA

0.10

 

IPTi with SP

Episodes

138

397

298

92

NA

49

 

PYAR

303

1405

637

709

NA

707

 

Incidence

0.46

0.25

0.47

0.13

NA

0.07

 

Efficacy (95% CI)

20 (−3, 38)

11 (−6, 26)

24 (7, 38)

2 (−30, 27)

NA

33 (0, 55)

18 (9, 27)

p-value

0.09

0.20

0.01

0.89

NA

0.05

0.001

NOTE: NA: Not available; PYAR: Person-years at risk. The committee used Stata to calculate the overall efficacy and its 95 percent confidence limit.

SOURCE: Data from the Report of the Statistical Working Group (IPTi Consortium, 2007b).

Page
37